AU2015213900B2 - Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists - Google Patents
Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists Download PDFInfo
- Publication number
- AU2015213900B2 AU2015213900B2 AU2015213900A AU2015213900A AU2015213900B2 AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2 AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- carboxylate
- hydrocarbon group
- compound according
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)C(CN(C)CC1)C1c1nnn[n]1 Chemical compound CC(*)C(CN(C)CC1)C1c1nnn[n]1 0.000 description 4
- RXNZFHIEDZEUQM-UHFFFAOYSA-N Brc1ncc[s]1 Chemical compound Brc1ncc[s]1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- OGXJEVCPEZGSKJ-UHFFFAOYSA-N C(CC1c2ccn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2ccn[nH]2)CN1C1CCNCC1 OGXJEVCPEZGSKJ-UHFFFAOYSA-N 0.000 description 1
- KHHSPOJLJYEDCI-UHFFFAOYSA-N C(CC1c2nnn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2nnn[nH]2)CN1C1CCNCC1 KHHSPOJLJYEDCI-UHFFFAOYSA-N 0.000 description 1
- YDKMMXBPUCTFTD-UHFFFAOYSA-N C(CNCC1)C1c1nnc[o]1 Chemical compound C(CNCC1)C1c1nnc[o]1 YDKMMXBPUCTFTD-UHFFFAOYSA-N 0.000 description 1
- RTDUCVVITRHYSA-LLVKDONJSA-N C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 Chemical compound C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 RTDUCVVITRHYSA-LLVKDONJSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1=O)=O ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- GMADLJSGNUJUCH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O GMADLJSGNUJUCH-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N)=O LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- YGUAGAZZHWMLLO-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O Chemical compound CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O YGUAGAZZHWMLLO-UHFFFAOYSA-N 0.000 description 1
- DMSLPGMAUARSMT-UHFFFAOYSA-N CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O DMSLPGMAUARSMT-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N CC(C)(C)OC(NN)=O Chemical compound CC(C)(C)OC(NN)=O DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- BZCFPFKKLNRCPS-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC BZCFPFKKLNRCPS-UHFFFAOYSA-N 0.000 description 1
- NOVPYXFYTVFXEP-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C NOVPYXFYTVFXEP-UHFFFAOYSA-N 0.000 description 1
- JRAQWFWKNASODJ-GPJFCIFZSA-N CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C JRAQWFWKNASODJ-GPJFCIFZSA-N 0.000 description 1
- SOFPALOKSUJISL-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O SOFPALOKSUJISL-UHFFFAOYSA-N 0.000 description 1
- VTNPTBFHPQBIKL-OBXNSHGQSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C VTNPTBFHPQBIKL-OBXNSHGQSA-N 0.000 description 1
- ZEYUGSOCURRXDF-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C ZEYUGSOCURRXDF-UHFFFAOYSA-N 0.000 description 1
- CGBLHVUOZYKMCK-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O CGBLHVUOZYKMCK-UHFFFAOYSA-N 0.000 description 1
- YAEGLMIBYIVZJZ-MRVPVSSYSA-N CC[C@H](CO1)N(C2CCNCC2)C1=O Chemical compound CC[C@H](CO1)N(C2CCNCC2)C1=O YAEGLMIBYIVZJZ-MRVPVSSYSA-N 0.000 description 1
- FMVBKBKOFVMNBG-UHFFFAOYSA-N CCc1nnc(C2CCN(C)CC2)[nH]1 Chemical compound CCc1nnc(C2CCN(C)CC2)[nH]1 FMVBKBKOFVMNBG-UHFFFAOYSA-N 0.000 description 1
- POTGJWFWPGMYQU-UHFFFAOYSA-N CN(CC1)CCC1N(CCCCC1)C1=O Chemical compound CN(CC1)CCC1N(CCCCC1)C1=O POTGJWFWPGMYQU-UHFFFAOYSA-N 0.000 description 1
- RPYSGPRTWAWWKK-UHFFFAOYSA-N COC(C(C1)NCC1(F)F)=O Chemical compound COC(C(C1)NCC1(F)F)=O RPYSGPRTWAWWKK-UHFFFAOYSA-N 0.000 description 1
- TUHWWSSACZIKGL-UHFFFAOYSA-N COC(C(CCCCC1)N1C1CCNCC1)=O Chemical compound COC(C(CCCCC1)N1C1CCNCC1)=O TUHWWSSACZIKGL-UHFFFAOYSA-N 0.000 description 1
- XZXVCMHKFUIDRV-LLVKDONJSA-N COC([C@@H](CCCC1)N1C1CCNCC1)=O Chemical compound COC([C@@H](CCCC1)N1C1CCNCC1)=O XZXVCMHKFUIDRV-LLVKDONJSA-N 0.000 description 1
- VVLRTXDYAWKZDG-UHFFFAOYSA-N Cc1nnn[n]1C1CCN(C)CC1 Chemical compound Cc1nnn[n]1C1CCN(C)CC1 VVLRTXDYAWKZDG-UHFFFAOYSA-N 0.000 description 1
- DRGIBGLITUBVOS-UHFFFAOYSA-N Cc1nnn[n]1C1CCNCC1 Chemical compound Cc1nnn[n]1C1CCNCC1 DRGIBGLITUBVOS-UHFFFAOYSA-N 0.000 description 1
- XPPFWBVTWIQNJV-UHFFFAOYSA-N O=S(OCC(F)(F)F)(S(F)(F)F)=O Chemical compound O=S(OCC(F)(F)F)(S(F)(F)F)=O XPPFWBVTWIQNJV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201579A AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402013.5A GB201402013D0 (en) | 2014-02-06 | 2014-02-06 | Pharmaceutical compounds |
| GB1402013.5 | 2014-02-06 | ||
| GBGB1416622.7A GB201416622D0 (en) | 2014-09-19 | 2014-09-19 | Pharmaceutical compounds |
| GB1416622.7 | 2014-09-19 | ||
| PCT/GB2015/050331 WO2015118342A1 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Division AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015213900A1 AU2015213900A1 (en) | 2016-08-11 |
| AU2015213900B2 true AU2015213900B2 (en) | 2018-12-13 |
Family
ID=52465550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015213900A Active AU2015213900B2 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9670183B2 (https=) |
| EP (4) | EP3102568B1 (https=) |
| JP (7) | JP6479029B2 (https=) |
| KR (1) | KR102352388B1 (https=) |
| CN (2) | CN109851610B (https=) |
| AU (3) | AU2015213900B2 (https=) |
| BR (1) | BR112016017979B1 (https=) |
| CA (1) | CA2938169C (https=) |
| CL (1) | CL2016001983A1 (https=) |
| CY (1) | CY1120834T1 (https=) |
| DK (2) | DK3102568T3 (https=) |
| ES (2) | ES2986327T3 (https=) |
| FI (1) | FI3406609T3 (https=) |
| HR (2) | HRP20241145T1 (https=) |
| HU (1) | HUE068301T2 (https=) |
| IL (1) | IL247117B (https=) |
| LT (2) | LT3102568T (https=) |
| MX (2) | MX371529B (https=) |
| NZ (1) | NZ723103A (https=) |
| PH (1) | PH12016501570A1 (https=) |
| PL (2) | PL3102568T3 (https=) |
| PT (2) | PT3102568T (https=) |
| RS (2) | RS57843B1 (https=) |
| RU (1) | RU2685230C2 (https=) |
| SA (1) | SA516371614B1 (https=) |
| SG (1) | SG11201606269WA (https=) |
| SI (2) | SI3406609T1 (https=) |
| SM (1) | SMT202400446T1 (https=) |
| UA (1) | UA122121C2 (https=) |
| WO (1) | WO2015118342A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| PT3478679T (pt) | 2016-07-01 | 2021-06-30 | Pfizer | Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11274100B2 (en) | 2017-06-21 | 2022-03-15 | Daiichi Sankyo Company, Limited | EP300/CREBBP inhibitor |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019027860A1 (en) * | 2017-08-01 | 2019-02-07 | Boehringer Ingelheim International Gmbh | INTERMEDIATE COMPOUNDS AND METHODS |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| PT3768669T (pt) * | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2021070090A1 (en) * | 2019-10-09 | 2021-04-15 | Novartis Ag | 2-azaspiro[3.4]octane derivatives as m4 agonists |
| CN119390705A (zh) * | 2019-10-09 | 2025-02-07 | 诺华股份有限公司 | 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物 |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| JP7707176B2 (ja) * | 2020-02-05 | 2025-07-14 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | ムスカリン性受容体４アンタゴニストおよび使用方法 |
| US11912705B2 (en) * | 2020-08-20 | 2024-02-27 | The Corporation Of Mercer University | Cathinone derivatives, pharmaceutical formulations, and methods |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| TW202416955A (zh) | 2022-08-04 | 2024-05-01 | 英商海普泰爾思治療公司 | 毒蕈鹼受體激動劑 |
| CN120344513A (zh) * | 2022-09-16 | 2025-07-18 | 赛尔维治疗有限责任公司 | M4活化剂/调节剂及其用途 |
| KR20250133755A (ko) * | 2023-01-12 | 2025-09-08 | 세레벨 쎄라퓨틱스, 엘엘씨 | M4 활성제/조절제로서의 스피로 유도체 및 이의 용도 |
| WO2024158645A1 (en) | 2023-01-24 | 2024-08-02 | Neurocrine Biosciences, Inc. | Deuterated compounds |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| WO2025030095A1 (en) | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
| WO2026050229A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050231A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a bipolar disorder |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
| WO2026050278A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist |
| WO2026050238A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder |
| WO2026050225A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| JPWO2002085890A1 (ja) * | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| KR20070034524A (ko) * | 2004-05-28 | 2007-03-28 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린 수용체 조정자 |
| AU2006330866A1 (en) | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| AU2007221214A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| AU2007226715A1 (en) * | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| GB0706188D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| MX2011004340A (es) | 2008-10-29 | 2011-05-23 | Gruenenthal Gmbh | Espiroaminas sustituidas. |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| TW201211028A (en) * | 2010-08-10 | 2012-03-16 | Dainippon Sumitomo Pharma Co | Fused ring pyrrolidine derivatives |
| WO2014177982A1 (en) | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| EA033866B1 (ru) | 2014-02-06 | 2019-12-03 | Рибосайенс Ллк | 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа |
| SG11201606269WA (en) * | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| MA53352A (fr) | 2014-09-19 | 2021-09-15 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
| PE20170937A1 (es) | 2014-09-19 | 2017-07-13 | Glaxosmithkline Ip Dev Ltd | Nuevos activadores de la guanilato ciclasa soluble y su uso |
-
2015
- 2015-02-06 SG SG11201606269WA patent/SG11201606269WA/en unknown
- 2015-02-06 PL PL15703826T patent/PL3102568T3/pl unknown
- 2015-02-06 SI SI201532034T patent/SI3406609T1/sl unknown
- 2015-02-06 CN CN201910003375.6A patent/CN109851610B/zh active Active
- 2015-02-06 LT LTEP15703826.6T patent/LT3102568T/lt unknown
- 2015-02-06 WO PCT/GB2015/050331 patent/WO2015118342A1/en not_active Ceased
- 2015-02-06 MX MX2016010322A patent/MX371529B/es active IP Right Grant
- 2015-02-06 HR HRP20241145TT patent/HRP20241145T1/hr unknown
- 2015-02-06 JP JP2016550483A patent/JP6479029B2/ja active Active
- 2015-02-06 UA UAA201609185A patent/UA122121C2/uk unknown
- 2015-02-06 BR BR112016017979-0A patent/BR112016017979B1/pt active IP Right Grant
- 2015-02-06 NZ NZ723103A patent/NZ723103A/en unknown
- 2015-02-06 EP EP15703826.6A patent/EP3102568B1/en active Active
- 2015-02-06 FI FIEP18179258.1T patent/FI3406609T3/fi active
- 2015-02-06 ES ES18179258T patent/ES2986327T3/es active Active
- 2015-02-06 SM SM20240446T patent/SMT202400446T1/it unknown
- 2015-02-06 LT LTEP18179258.1T patent/LT3406609T/lt unknown
- 2015-02-06 US US15/117,018 patent/US9670183B2/en active Active
- 2015-02-06 PL PL18179258.1T patent/PL3406609T3/pl unknown
- 2015-02-06 MX MX2020001236A patent/MX393637B/es unknown
- 2015-02-06 HR HRP20181499TT patent/HRP20181499T1/hr unknown
- 2015-02-06 DK DK15703826.6T patent/DK3102568T3/en active
- 2015-02-06 AU AU2015213900A patent/AU2015213900B2/en active Active
- 2015-02-06 PT PT15703826T patent/PT3102568T/pt unknown
- 2015-02-06 ES ES15703826.6T patent/ES2688548T3/es active Active
- 2015-02-06 CN CN201580017993.6A patent/CN106458986B/zh active Active
- 2015-02-06 EP EP26156152.6A patent/EP4714446A2/en active Pending
- 2015-02-06 CA CA2938169A patent/CA2938169C/en active Active
- 2015-02-06 SI SI201530399T patent/SI3102568T1/sl unknown
- 2015-02-06 EP EP18179258.1A patent/EP3406609B1/en active Active
- 2015-02-06 HU HUE18179258A patent/HUE068301T2/hu unknown
- 2015-02-06 RS RS20181127A patent/RS57843B1/sr unknown
- 2015-02-06 PT PT181792581T patent/PT3406609T/pt unknown
- 2015-02-06 DK DK18179258.1T patent/DK3406609T3/da active
- 2015-02-06 RS RS20240960A patent/RS65894B1/sr unknown
- 2015-02-06 RU RU2016133684A patent/RU2685230C2/ru active
- 2015-02-06 KR KR1020167024572A patent/KR102352388B1/ko active Active
- 2015-02-06 EP EP24177415.7A patent/EP4413985B1/en active Active
-
2016
- 2016-08-04 SA SA516371614A patent/SA516371614B1/ar unknown
- 2016-08-04 IL IL247117A patent/IL247117B/en active IP Right Grant
- 2016-08-05 CL CL2016001983A patent/CL2016001983A1/es unknown
- 2016-08-08 PH PH12016501570A patent/PH12016501570A1/en unknown
-
2017
- 2017-05-10 US US15/591,605 patent/US9926297B2/en active Active
-
2018
- 2018-02-22 US US15/902,537 patent/US10196380B2/en active Active
- 2018-09-27 CY CY181100996T patent/CY1120834T1/el unknown
- 2018-12-12 US US16/217,570 patent/US10385039B2/en active Active
-
2019
- 2019-02-01 JP JP2019017086A patent/JP6774513B2/ja active Active
- 2019-03-07 AU AU2019201579A patent/AU2019201579B2/en active Active
- 2019-07-01 US US16/459,179 patent/US10689368B2/en active Active
-
2020
- 2020-06-17 US US16/904,099 patent/US10961225B2/en active Active
- 2020-10-05 JP JP2020168341A patent/JP2021006571A/ja not_active Withdrawn
- 2020-11-26 AU AU2020277225A patent/AU2020277225A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060030A patent/JP7652829B2/ja active Active
- 2023-05-02 JP JP2023076024A patent/JP7652832B2/ja active Active
- 2023-05-02 JP JP2023076025A patent/JP7652833B2/ja active Active
-
2025
- 2025-03-14 JP JP2025041135A patent/JP2025085736A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| US9266857B2 (en) * | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10961225B2 (en) | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | |
| CA2994143C (en) | Muscarinic agonists | |
| HK40114593A (en) | Pharmaceutical compounds | |
| RU2811601C1 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| RU2811601C9 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| HK1231473B (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
| HK40007500A (en) | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |